Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Start Date
2/23/2024
Completion Date
2/23/2029
Summary
Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard surgical management during surgery. The researchers think acute normovolemic hemodilution/ANH may decrease the need for allogenic blood transfusion/ABT in people having primary cytoreductive surgery.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Acute Normovolemic Hemodilution/ANH
Conditions
Locations
Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey 07920
United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey 07748
United States
Memorial Sloan Kettering Bergen (Limited protocol activities)
Montvale, New Jersey 07645
United States
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)
Commack, New York 11725
United States
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, New York 10604
United States
Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, New York 10065
United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York 11553
United States